Green Therapeutic Biocapsules: Using Plant Cells to Orally Deliver Biopharmaceuticals

Rosales‐Mendoza, Sergio; Nieto-Gómez, Ricardo

doi:10.1016/j.tibtech.2018.05.010

Cited by 24 publications

(15 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another important approach is chloroplast transformation, which integrates the target gene into the chloroplast genome and thereby leads to extremely high levels of protein production (Staub et al, 2000;Verma and Daniell, 2007;Zhang et al, 2017); the transgenic approach, which integrates foreign genes into the plant nuclear genome, is also widely used (Lee et al, 2015;Sohn et al, 2018;Twyman et al, 2002). Many different strategies using transgenic plants can be employed as recombinant proteins can be obtained from either whole plants or cell cultures (Holtz et al, 2015; Rosales-Mendoza and Nieto-G omez, 2018;Tekoah et al, 2015). Carrot cell cultures have been used to produce taliglucerase-a which is used to treat Gausher's disease.…”

Section: Introductionmentioning

confidence: 99%

Cost‐effective production of tag‐less recombinant protein in Nicotiana benthamiana

Islam

Kwak

Lee

et al. 2018

Plant Biotechnology Journal

View full text Add to dashboard Cite

Summary Plants have recently received a great deal of attention as a means of producing recombinant proteins. Despite this, a limited number of recombinant proteins are currently on the market and, if plants are to be more widely used, a cost‐effective and efficient purification method is urgently needed. Although affinity tags are convenient tools for protein purification, the presence of a tag on the recombinant protein is undesirable for many applications. A cost‐effective method of purification using an affinity tag and the removal of the tag after purification has been developed. The family 3 cellulose‐binding domain ( CBM 3), which binds to microcrystalline cellulose, served as the affinity tag and the small ubiquitin‐related modifier ( SUMO ) and SUMO ‐specific protease were used to remove it. This method, together with size‐exclusion chromatography, enabled purification of human interleukin‐6 ( hIL 6) with a yield of 18.49 mg/kg fresh weight from leaf extracts of Nicotiana benthamiana following Agrobacterium ‐mediated transient expression. Plant‐produced hIL 6 (P‐ hIL 6) contained less than 0.2 EU/μg (0.02 ng/mL) endotoxin. P‐ hIL 6 activated the Janus kinase‐signal transducer and activator of transcriptional pathways in human LNC aP cells, and induced expression of IL ‐21 in activated mouse CD 4 + T cells. This approach is thus a powerful method for producing recombinant proteins in plants.

show abstract

Section: Introductionmentioning

confidence: 99%

Cost‐effective production of tag‐less recombinant protein in Nicotiana benthamiana

Islam

Kwak

Lee

et al. 2018

Plant Biotechnology Journal

View full text Add to dashboard Cite

show abstract

“…The design of LTB/CTB-based chimeras carrying SARS-CoV-2 epitopes is an interesting approach that should be explored. Proline-containing linkers have been used to properly display unrelated antigens without altering the ability of those carriers to form the pentameric structure responsible for GM1 binding [57]. The accumulation of those chimeric proteins in the ER is advisable, although toxicity has been reported for some plants accumulating high levels of those recombinant proteins [87].…”

Section: Multiepitopic Vaccinesmentioning

confidence: 99%

What Does Plant-Based Vaccine Technology Offer to the Fight against COVID-19?

et al. 2020

Self Cite

View full text Add to dashboard Cite

The emergence of new pathogenic viral strains is a constant threat to global health, with the new coronavirus strain COVID-19 as the latest example. COVID-19, caused by the SARS-CoV-2 virus has quickly spread around the globe. This pandemic demands rapid development of drugs and vaccines. Plant-based vaccines are a technology with proven viability, which have led to promising results for candidates evaluated at the clinical level, meaning this technology could contribute towards the fight against COVID-19. Herein, a perspective in how plant-based vaccines can be developed against COVID-19 is presented. Injectable vaccines could be generated by using transient expression systems, which offer the highest protein yields and are already adopted at the industrial level to produce VLPs-vaccines and other biopharmaceuticals under GMPC-processes. Stably-transformed plants are another option, but this approach requires more time for the development of antigen-producing lines. Nonetheless, this approach offers the possibility of developing oral vaccines in which the plant cell could act as the antigen delivery agent. Therefore, this is the most attractive approach in terms of cost, easy delivery, and mucosal immunity induction. The development of multiepitope, rationally-designed vaccines is also discussed regarding the experience gained in expression of chimeric immunogenic proteins in plant systems.

show abstract

“…Several examples of such PMPs and the detailed advantages, limitations and challenges of plant expression system for the production of the desired targets have been comprehensively reviewed elsewhere [ 121 , 122 , 123 , 124 , 125 , 126 , 127 , 128 ]. The different plant-based expression systems range from transgenic plants to cell suspensions cultures are available for AMP production in plants [ 129 , 130 , 131 , 132 , 133 ] which are described briefly in the following sections.…”

Section: Plant Molecular Farmingmentioning

confidence: 99%

Biotechnological Insights on the Expression and Production of Antimicrobial Peptides in Plants

Shanmugaraj¹,

Bulaon

Malla³

et al. 2021

Molecules

View full text Add to dashboard Cite

The emergence of drug-resistant pathogens poses a serious critical threat to global public health and requires immediate action. Antimicrobial peptides (AMPs) are a class of short peptides ubiquitously found in all living forms, including plants, insects, mammals, microorganisms and play a significant role in host innate immune system. These peptides are considered as promising candidates to treat microbial infections due to its distinct advantages over conventional antibiotics. Given their potent broad spectrum of antimicrobial action, several AMPs are currently being evaluated in preclinical/clinical trials. However, large quantities of highly purified AMPs are vital for basic research and clinical settings which is still a major bottleneck hindering its application. This can be overcome by genetic engineering approaches to produce sufficient amount of diverse peptides in heterologous host systems. Recently plants are considered as potential alternatives to conventional protein production systems such as microbial and mammalian platforms due to their unique advantages such as rapidity, scalability and safety. In addition, AMPs can also be utilized for development of novel approaches for plant protection thereby increasing the crop yield. Hence, in order to provide a spotlight for the expression of AMP in plants for both clinical or agricultural use, the present review presents the importance of AMPs and efforts aimed at producing recombinant AMPs in plants for molecular farming and plant protection so far.

show abstract

Green Therapeutic Biocapsules: Using Plant Cells to Orally Deliver Biopharmaceuticals

Cited by 24 publications

References 54 publications

Cost‐effective production of tag‐less recombinant protein in Nicotiana benthamiana

Cost‐effective production of tag‐less recombinant protein in Nicotiana benthamiana

What Does Plant-Based Vaccine Technology Offer to the Fight against COVID-19?

Biotechnological Insights on the Expression and Production of Antimicrobial Peptides in Plants

Contact Info

Product

Resources

About